Case report: Selpercatinib in the treatment of RET fusion-positive advanced lung adenocarcinoma: a challenging clinical case
BackgroundRearranged during transfection (RET) fusions represent a distinct molecular subset of non-small cell lung cancer (NSCLC) with targeted therapeutic potential. Selpercatinib, a highly selective RET inhibitor, has demonstrated efficacy in various solid tumors harboring RET alterations. Here,...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1500449/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841527918506803200 |
|---|---|
| author | Raffaella Pagliaro Raffaella Pagliaro Paola Maria Medusa Paola Maria Medusa Fabiana Vitiello Luigi Aronne Luigi Aronne Susan F. M. Campbell Susan F. M. Campbell Fabio Perrotta Fabio Perrotta Andrea Bianco Andrea Bianco |
| author_facet | Raffaella Pagliaro Raffaella Pagliaro Paola Maria Medusa Paola Maria Medusa Fabiana Vitiello Luigi Aronne Luigi Aronne Susan F. M. Campbell Susan F. M. Campbell Fabio Perrotta Fabio Perrotta Andrea Bianco Andrea Bianco |
| author_sort | Raffaella Pagliaro |
| collection | DOAJ |
| description | BackgroundRearranged during transfection (RET) fusions represent a distinct molecular subset of non-small cell lung cancer (NSCLC) with targeted therapeutic potential. Selpercatinib, a highly selective RET inhibitor, has demonstrated efficacy in various solid tumors harboring RET alterations. Here, we present a case highlighting the use and clinical outcomes of selpercatinib in a patient diagnosed with advanced lung adenocarcinoma harboring a RET fusion.Case presentationA 59-year-old woman with a history of stage IV lung adenocarcinoma harboring a KIF5B-RET fusion presented with disease progression following first-line chemo-immunotherapy. Selpercatinib was initiated as a targeted therapy, leading to a notable radiographic response and clinical improvement. The patient experienced a significant reduction in tumor burden and reported improved symptom control, with no significant adverse effects during the 21-month follow-up period.ConclusionsThis case highlights the efficacy and tolerability of selpercatinib in treating advanced lung adenocarcinoma with a RET fusion. The observed clinical response supports the early use of selpercatinib as a targeted therapy for RET fusion-positive NSCLC, including in patients with compromised general and respiratory conditions, especially in cases refractory to conventional treatments. Long-term follow-up studies are warranted to validate these findings and assess the durability of responses. |
| format | Article |
| id | doaj-art-a5ff7c9fb2d54f969b8c5af808c6b96a |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-a5ff7c9fb2d54f969b8c5af808c6b96a2025-01-15T05:10:27ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-01-011410.3389/fonc.2024.15004491500449Case report: Selpercatinib in the treatment of RET fusion-positive advanced lung adenocarcinoma: a challenging clinical caseRaffaella Pagliaro0Raffaella Pagliaro1Paola Maria Medusa2Paola Maria Medusa3Fabiana Vitiello4Luigi Aronne5Luigi Aronne6Susan F. M. Campbell7Susan F. M. Campbell8Fabio Perrotta9Fabio Perrotta10Andrea Bianco11Andrea Bianco12Department of Translational Medical Sciences University of Campania L. Vanvitelli, Naples, ItalyClinic of Respiratory Diseases “Vanvitelli”, A.O. dei Colli, Monaldi Hospital, Naples, ItalyDepartment of Translational Medical Sciences University of Campania L. Vanvitelli, Naples, ItalyDepartment of Pneumology and Oncology, Monaldi Hospital A.O. Dei Colli, Naples, ItalyDepartment of Pneumology and Oncology, Monaldi Hospital A.O. Dei Colli, Naples, ItalyDepartment of Translational Medical Sciences University of Campania L. Vanvitelli, Naples, ItalyClinic of Respiratory Diseases “Vanvitelli”, A.O. dei Colli, Monaldi Hospital, Naples, ItalyDepartment of Translational Medical Sciences University of Campania L. Vanvitelli, Naples, ItalyClinic of Respiratory Diseases “Vanvitelli”, A.O. dei Colli, Monaldi Hospital, Naples, ItalyDepartment of Translational Medical Sciences University of Campania L. Vanvitelli, Naples, ItalyClinic of Respiratory Diseases “Vanvitelli”, A.O. dei Colli, Monaldi Hospital, Naples, ItalyDepartment of Translational Medical Sciences University of Campania L. Vanvitelli, Naples, ItalyClinic of Respiratory Diseases “Vanvitelli”, A.O. dei Colli, Monaldi Hospital, Naples, ItalyBackgroundRearranged during transfection (RET) fusions represent a distinct molecular subset of non-small cell lung cancer (NSCLC) with targeted therapeutic potential. Selpercatinib, a highly selective RET inhibitor, has demonstrated efficacy in various solid tumors harboring RET alterations. Here, we present a case highlighting the use and clinical outcomes of selpercatinib in a patient diagnosed with advanced lung adenocarcinoma harboring a RET fusion.Case presentationA 59-year-old woman with a history of stage IV lung adenocarcinoma harboring a KIF5B-RET fusion presented with disease progression following first-line chemo-immunotherapy. Selpercatinib was initiated as a targeted therapy, leading to a notable radiographic response and clinical improvement. The patient experienced a significant reduction in tumor burden and reported improved symptom control, with no significant adverse effects during the 21-month follow-up period.ConclusionsThis case highlights the efficacy and tolerability of selpercatinib in treating advanced lung adenocarcinoma with a RET fusion. The observed clinical response supports the early use of selpercatinib as a targeted therapy for RET fusion-positive NSCLC, including in patients with compromised general and respiratory conditions, especially in cases refractory to conventional treatments. Long-term follow-up studies are warranted to validate these findings and assess the durability of responses.https://www.frontiersin.org/articles/10.3389/fonc.2024.1500449/fulllung adenocarcinomaRET fusionselpercatinibtargeted therapyprecision medicine |
| spellingShingle | Raffaella Pagliaro Raffaella Pagliaro Paola Maria Medusa Paola Maria Medusa Fabiana Vitiello Luigi Aronne Luigi Aronne Susan F. M. Campbell Susan F. M. Campbell Fabio Perrotta Fabio Perrotta Andrea Bianco Andrea Bianco Case report: Selpercatinib in the treatment of RET fusion-positive advanced lung adenocarcinoma: a challenging clinical case Frontiers in Oncology lung adenocarcinoma RET fusion selpercatinib targeted therapy precision medicine |
| title | Case report: Selpercatinib in the treatment of RET fusion-positive advanced lung adenocarcinoma: a challenging clinical case |
| title_full | Case report: Selpercatinib in the treatment of RET fusion-positive advanced lung adenocarcinoma: a challenging clinical case |
| title_fullStr | Case report: Selpercatinib in the treatment of RET fusion-positive advanced lung adenocarcinoma: a challenging clinical case |
| title_full_unstemmed | Case report: Selpercatinib in the treatment of RET fusion-positive advanced lung adenocarcinoma: a challenging clinical case |
| title_short | Case report: Selpercatinib in the treatment of RET fusion-positive advanced lung adenocarcinoma: a challenging clinical case |
| title_sort | case report selpercatinib in the treatment of ret fusion positive advanced lung adenocarcinoma a challenging clinical case |
| topic | lung adenocarcinoma RET fusion selpercatinib targeted therapy precision medicine |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1500449/full |
| work_keys_str_mv | AT raffaellapagliaro casereportselpercatinibinthetreatmentofretfusionpositiveadvancedlungadenocarcinomaachallengingclinicalcase AT raffaellapagliaro casereportselpercatinibinthetreatmentofretfusionpositiveadvancedlungadenocarcinomaachallengingclinicalcase AT paolamariamedusa casereportselpercatinibinthetreatmentofretfusionpositiveadvancedlungadenocarcinomaachallengingclinicalcase AT paolamariamedusa casereportselpercatinibinthetreatmentofretfusionpositiveadvancedlungadenocarcinomaachallengingclinicalcase AT fabianavitiello casereportselpercatinibinthetreatmentofretfusionpositiveadvancedlungadenocarcinomaachallengingclinicalcase AT luigiaronne casereportselpercatinibinthetreatmentofretfusionpositiveadvancedlungadenocarcinomaachallengingclinicalcase AT luigiaronne casereportselpercatinibinthetreatmentofretfusionpositiveadvancedlungadenocarcinomaachallengingclinicalcase AT susanfmcampbell casereportselpercatinibinthetreatmentofretfusionpositiveadvancedlungadenocarcinomaachallengingclinicalcase AT susanfmcampbell casereportselpercatinibinthetreatmentofretfusionpositiveadvancedlungadenocarcinomaachallengingclinicalcase AT fabioperrotta casereportselpercatinibinthetreatmentofretfusionpositiveadvancedlungadenocarcinomaachallengingclinicalcase AT fabioperrotta casereportselpercatinibinthetreatmentofretfusionpositiveadvancedlungadenocarcinomaachallengingclinicalcase AT andreabianco casereportselpercatinibinthetreatmentofretfusionpositiveadvancedlungadenocarcinomaachallengingclinicalcase AT andreabianco casereportselpercatinibinthetreatmentofretfusionpositiveadvancedlungadenocarcinomaachallengingclinicalcase |